Drugs Made In America Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing February 25, 2025
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) has announced that starting February 25, 2025, holders of units from the company's initial public offering can separately trade ordinary shares and rights. The separated components will trade on The Nasdaq Global Market under the symbols 'DMAA' for ordinary shares and 'DMAAR' for rights, while unseparated units will continue trading as 'DMAAU'.
Unit holders must contact VStock Transfer through their brokers to separate units. Only whole rights will be traded, with no fractional rights issued. The unit offering was conducted through a prospectus available from Clear Street. A registration statement (333-281170) for these securities was declared effective on January 7, 2025, with a post-effective amendment effective on January 27, 2025.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) ha annunciato che a partire dal 25 febbraio 2025, i possessori di unità dell'offerta pubblica iniziale della società potranno scambiare separatamente le azioni ordinarie e i diritti. I componenti separati verranno scambiati sul Nasdaq Global Market con i simboli 'DMAA' per le azioni ordinarie e 'DMAAR' per i diritti, mentre le unità non separate continueranno a essere scambiate come 'DMAAU'.
I possessori di unità devono contattare VStock Transfer tramite i propri broker per separare le unità. Solo i diritti interi saranno scambiati, senza diritti frazionari emessi. L'offerta di unità è stata condotta tramite un prospetto disponibile da Clear Street. Una dichiarazione di registrazione (333-281170) per questi titoli è stata dichiarata efficace il 7 gennaio 2025, con un emendamento post-efficace in vigore il 27 gennaio 2025.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) ha anunciado que a partir del 25 de febrero de 2025, los titulares de unidades de la oferta pública inicial de la compañía podrán negociar por separado acciones ordinarias y derechos. Los componentes separados se negociarán en el Nasdaq Global Market bajo los símbolos 'DMAA' para las acciones ordinarias y 'DMAAR' para los derechos, mientras que las unidades no separadas continuarán negociándose como 'DMAAU'.
Los titulares de unidades deben contactar a VStock Transfer a través de sus corredores para separar las unidades. Solo se negociarán derechos enteros, sin derechos fraccionarios emitidos. La oferta de unidades se llevó a cabo a través de un prospecto disponible de Clear Street. Una declaración de registro (333-281170) para estos valores fue declarada efectiva el 7 de enero de 2025, con una enmienda post-efectiva que entró en vigor el 27 de enero de 2025.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU)는 2025년 2월 25일부터 회사의 초기 공모 주식 보유자들이 보통주와 권리를 별도로 거래할 수 있다고 발표했습니다. 분리된 구성 요소는 Nasdaq Global Market에서 보통주에 대해 'DMAA' 기호로, 권리에 대해 'DMAAR' 기호로 거래되며, 분리되지 않은 단위는 계속해서 'DMAAU'로 거래됩니다.
단위 보유자는 단위를 분리하기 위해 자신의 중개인을 통해 VStock Transfer에 연락해야 합니다. 전체 권리만 거래되며, 분할 권리는 발행되지 않습니다. 단위 제공은 Clear Street에서 제공되는 설명서를 통해 이루어졌습니다. 이 증권에 대한 등록 진술서(333-281170)는 2025년 1월 7일에 효력이 발생했으며, 2025년 1월 27일에 효력이 발생하는 후속 수정이 있었습니다.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) a annoncé qu'à partir du 25 février 2025, les détenteurs d'unités de l'offre publique initiale de la société pourront négocier séparément des actions ordinaires et des droits. Les composants séparés seront négociés sur le Nasdaq Global Market sous les symboles 'DMAA' pour les actions ordinaires et 'DMAAR' pour les droits, tandis que les unités non séparées continueront à être négociées sous 'DMAAU'.
Les détenteurs d'unités doivent contacter VStock Transfer par l'intermédiaire de leurs courtiers pour séparer les unités. Seuls des droits entiers seront négociés, sans droits fractionnaires émis. L'offre d'unités a été réalisée par le biais d'un prospectus disponible auprès de Clear Street. Une déclaration d'enregistrement (333-281170) pour ces titres a été déclarée effective le 7 janvier 2025, avec un amendement post-efficace qui entrera en vigueur le 27 janvier 2025.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) hat angekündigt, dass ab dem 25. Februar 2025 Inhaber von Einheiten aus dem Börsengang des Unternehmens die Stammaktien und Rechte separat handeln können. Die separierten Komponenten werden an der Nasdaq Global Market unter den Symbolen 'DMAA' für Stammaktien und 'DMAAR' für Rechte gehandelt, während nicht separierte Einheiten weiterhin als 'DMAAU' gehandelt werden.
Einheiteninhaber müssen VStock Transfer über ihre Broker kontaktieren, um die Einheiten zu trennen. Es werden nur ganze Rechte gehandelt, ohne dass Bruchrechte ausgegeben werden. Das Angebot für Einheiten wurde über ein Prospekt durchgeführt, das bei Clear Street erhältlich ist. Eine Registrierungsmitteilung (333-281170) für diese Wertpapiere wurde am 7. Januar 2025 für wirksam erklärt, mit einer nachträglichen Änderung, die am 27. Januar 2025 wirksam wird.
- None.
- None.
Fort Lauderdale, Florida, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that, commencing February 25, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s ordinary shares and rights included in the units.
No fractional rights will be issued upon separation of the units and only whole rights will trade. The ordinary shares and rights that are separated will trade on The Nasdaq Global Market under the symbols “DMAA” and “DMAAR,” respectively. Those units not separated will continue to trade on The Nasdaq Global Market under the symbol “DMAAU.” Holders of units will need to have their brokers contact VStock Transfer LLC, the Company’s transfer agent, in order to separate the units into ordinary shares and rights.
The offering of the units was made only by means of a prospectus, copies of which may be obtained from Clear Street, Attn: Syndicate Department, 150 Greenwich Street, 45th floor, New York, NY 10007, or by email at ecm@clearstreet.io. A registration statement on Form S-1 (333-281170) relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on January 7, 2025, and a post-effective amendment to the registration statement was declared effective on January 27, 2025. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Drugs Made In America Acquisition Corp.
The Company is a blank check company incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company believes that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.
Cautionary Note Concerning Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the registration statement, as amended by the post-effective amendment, and the prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, www.sec.gov.
Contact Information
Drugs Made In America Acquisition Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
Lynn Stockwell
Chief Executive Officer and Executive Chair
Email: executive@dmaacorp.com
Phone: (954) 870-3099
FAQ
When will DMAAU units begin trading separately as shares and rights?
What are the new trading symbols for DMAAU's separated securities?
How can DMAAU unit holders separate their units into shares and rights?
When was the DMAAU registration statement declared effective by the SEC?
Will DMAAU issue fractional rights during the unit separation?
